4-Methyl-5,6,7,8-tetrahydroquinazoline-2-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-Methyl-5,6,7,8-tetrahydroquinazoline-2-thiol
• 英文别名: 4-methyl-5,6,7,8-tetrahydro-3H-quinazoline-2-thione
• 化学式: C₉H₁₂N₂S
• mdl: MFCD06251489
• 分子量: 180.27
• InChiKey: LZYWJYIMWLEDJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Substituted pyrimidines
  申请人：Gesing Rudolf F. Ernst

  公开号：US20050065166A1

  公开（公告）日：2005-03-24

  The invention relates to substituted pyrimidines of the general formula (I) in which n, R 1 , R 2 , R 3 and Z are as defined in the disclosure, to their use as crop treatment agents, in particular as herbicides, and to processes for their preparation.

  本发明涉及通式（I）的取代嘧啶 其中 n、R 1 , R 2 , R 3 和 Z 的定义，以及它们作为作物处理剂（尤其是除草剂）的用途和制备工艺。
• SUBSTITUIERTE PYRIMIDINE
  申请人：Bayer CropScience AG

  公开号：EP1444208A1

  公开（公告）日：2004-08-11
• COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB
  申请人：Warner-Lambert Company LLC

  公开号：EP1530467A2

  公开（公告）日：2005-05-18
• [DE] SUBSTITUIERTE PYRIMIDINE<br/>[EN] SUBSTITUTED PYRIMIDINES<br/>[FR] PYRIMIDINES SUBSTITUEES
  申请人：BAYER CROPSCIENCE AG

  公开号：WO2003037878A1

  公开（公告）日：2003-05-08

  Die Erfindung betrifft substituierte Pyrimidine der allgemeinen Formel (I), worin n, R?1, R2, R3¿ und Z die in der Beschreibung angegebene Bedeutung haben, ihre Verwendung als Pflanzenbehandlungsmittel, insbesondere Herbizide und Verfahren zu ihrer Herstellung.
• [EN] COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB<br/>[FR] COMBINAISON D'UN INHIBITEUR CARBOXYLIQUE ALLOSTERIQUE DE METALLOPROTEINASE-13 DE MATRICE ET DE CELECOXIBE OU DE VALDECOXIBE
  申请人：WARNER LAMBERT CO

  公开号：WO2004006912A2

  公开（公告）日：2004-01-22

  This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.